20个月！药明生物祝贺Aravive完成AVB-S6-500一期临床试验的机制验证
(*Please scroll down for English news.)
上海，2018年5月14日
全球领先的开放式生物技术平台公司药明生物（2269.HK），祝贺合作伙伴Aravive公司在短短20个月内顺利完成创新生物药AVB-S6-500从细胞株构建到一期临床试验的机制验证的工作。药明生物对此表示祝贺。
Aravive公司总部位于美国德克萨斯州，目前正在开展的AVB-S6-500项目一期临床试验研究有32名患者参与。公司通过单剂量爬坡试验进行分析，完成了AVB-S6-500对GAS6靶点中和效果的临床机制验证工作。
创新生物药AVB-S6-500是一种新型GAS6-AXL信号通路抑制剂，GAS6-AXL信号传导被认为是促进肿瘤生长及转移、肿瘤免疫逃逸与抵抗其他抗癌药物的关键分子通路，抑制GAS6-AXL信号通路已经成为研究癌症和特定纤维化疾病疗法的新机制。
“药明生物很荣幸能够赋能合作伙伴Aravive快速、高效、高质量地推进AVB-S6-500开发进程。我们很高兴该项目作为癌症和纤维化疾病的一种创新疗法所取得的重大进展。”药明生物首席执行官陈智胜博士表示，“我们将继续与Aravive就其研发管线开展合作，共同为全球市场带来更多创新生物药，造福全球病患。”
关于Aravive Biologics
Aravive是一家私人控股的生物制药公司，重点开发新型针对难治性恶性肿瘤与某些纤维化疾病的高度选择性疗法。公司候选的主攻方向是GAS6-AXL通路，该药物已在多种肿瘤模型中获得了诸多强有力的临床前研究数据并正在开展一期临床研究。公司总部位于美国德克萨斯州休斯顿市，并获得美国德克萨斯州癌症预防与研究所（CPRIT）的支持。欲了解更多信息，请访问公司官网：www.aravive.com。
关于药明生物
药明生物作为一家香港上市公司，是全球领先的开放式、一体化生物制药能力和技术平台。公司为全球生物制药公司和生物技术公司提供全方位的端到端研发服务，帮助任何人、任何公司发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。如需更多信息，请访问：www.wuxibiologics.com.cn。
WuXi Biologics Congratulates Aravive Biologics on Achieving Proof-of-Mechanism for Novel Biologic AVB-S6-500 within 20 Months from Cell Line Development
SHANGHAI, May 14, 2018
WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, congratulates its partner Aravive Biologics on achieving proof-of-mechanism for novel GAS6-AXL pathway inhibitor, AVB-S6-500, in ongoing Phase 1 trial 20 months after initiating cell line development.
Texas U.S. based Aravive Biologics, Inc. announced that the company has demonstrated clinical proof-of-mechanism for AVB-S6-500 in neutralizing GAS6, based on analysis of the single ascending dose portion of the ongoing Phase 1 study (32 subjects).
Research has shown GAS6-AXL signaling to be a key molecular pathway that is believed to promote tumor growth and metastasis, as well as tumor immune evasion and resistance to other anticancer agents. GAS6-AXL inhibition has shown potential as a strategy for the treatment of certain fibrotic diseases.
“WuXi Biologics is honored to enable Aravive to develop AVB-S6-500 with unsurpassed speed, efficiency and quality. We are very excited about the great progress of this first-in-class molecule as an innovative new therapy for people with cancers and fibrotic diseases,” said Dr. Chris Chen, Chief Executive Officer of WuXi Biologics. “We look forward to the collaboration with Aravive over the coming years on further molecules in its pipeline.”
About Aravive Biologics
Aravive Biologics is a privately held clinical stage biopharmaceutical company developing novel, highly selective therapies designed to treat serious cancers and certain fibrotic diseases. The company’s lead program is focused on the GAS6-AXL pathway. Aravive Biologics has generated strong preclinical data for its lead drug candidate AVB-S6-500 in a variety of cancer models and is currently conducting a Ph1 clinical study. The company is based in Houston, Texas, and receives support from the Cancer Prevention & Research Institute of Texas (CPRIT). For more information, please visit our website at http://www.aravive.com.
About WuXi Biologics
WuXi Biologics, a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. For more information on WuXi Biologics, please visit www.wuxibiologics.com.
注：本信息不构成药明生物的信息披露或投资建议
